Compare Citius Pharmaceuticals Inc (CTXR) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vale SA — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Vale SA trades at $13.48 (market cap $58.70B). The key difference: Vale SA is far larger — about 4256.7× Citius Pharmaceuticals Inc's market cap, and Vale SA pays a 8.75% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Vale SA for 109 Days on average.
| CTXR | VALE | |
|---|---|---|
Market Cap | $13.79M | $58.70B |
Volume | 156,684 | 45,073,516 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $17.82 |
52-Week Low | $0.48 | $10.75 |
Typical Hold Time | 16 Days | 109 Days |
Enterprise Value | $3.96M | $74.94B |
Dividend Yield | — | 8.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
VALE trades at $13.42, down 4.69% today amid broader sector weakness. The stock shows bearish technical signals with recent earnings misses and declining profit margins (5.11% net margin in 2025). Revenue has stabilized around $38-41B, but net income fell to $2.35B in 2025 from $18.8B in 2022. The company maintains strong cash flow generation ($8.8B operating cash flow) and recently declared a $0.40 dividend payable September 2026.
VALE faces headwinds from iron ore price volatility and rising costs, but base metals growth provides diversification. Analyst consensus is mixed with 32% buy ratings and a $16.21 price target suggesting 21% upside. Key risks include Brazilian regulatory exposure and cyclical commodity dependence. The current valuation (P/E 27.22) appears stretched given earnings compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
